Jeffrey Jones
Corewell Health West · Ohio State University · Celgene Corporation
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jeffrey Jones as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:32 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01716377 · Healing With Venlafaxine After Injury (HELP)Rhode Island Hospital · completed · Neck Pain · principal investigator
- Ph2NCT01206777 · Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell MalignanciesOhio State University Comprehensive Cancer Center · completed · Indolent or Intermediate Grade B-cell Malignancy · principal investigator
- Ph1NCT01126502 · Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic LeukemiaNational Cancer Institute (NCI) · terminated · B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma · principal investigator
- Ph3NCT00910910 · Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)Celgene · completed · B-Cell Chronic Lymphocytic Leukemia · study director
- Ph1/Ph2NCT00112723 · Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaNational Cancer Institute (NCI) · terminated · Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:32 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 15 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Kansas Animal Food Regulatory Program Standards MaintenanceU2FFD008685 · FDA · KANSAS STATE DEPARTMENT OF AGRICULTURE · fiscal years 2025 to 2026 · $270,816 awarded in 2026Same name and institution; not confirmed by an ID
- Kansas Maintenance of the Animal Feed Regulatory Program Standards with Optional Coordinated Preventative ControlU18FD007202 · FDA · KANSAS STATE DEPARTMENT OF AGRICULTURE · fiscal years 2020 to 2024 · $434,567 awarded in 2024Same name and institution; not confirmed by an ID
- Non-canonical Role of Ethanol-Inducible Cytochrome P450 Species in Alcohol-Drug Interactions and Alcohol-Related DisordersR21AA024548 · NIAAA · WASHINGTON STATE UNIVERSITY · fiscal years 2018 to 2019 · $181,688 awarded in 2019Same name and institution; not confirmed by an ID
- The Kansas Department of Agriculture's Implementation of the Animal Feed Regulatory Program Standards through a Cooperative AgreementU18FD005595 · FDA · KANSAS STATE DEPARTMENT OF AGRICULTURE · fiscal years 2018 to 2019 · $450,000 awarded in 2019Same name and institution; not confirmed by an ID
- Understanding the Metabolic Impact of Aldehyde Oxidase on New Drug DesignR01GM100874 · NIGMS · WASHINGTON STATE UNIVERSITY · fiscal years 2012 to 2019 · $392,397 awarded in 2019Same name and institution; not confirmed by an ID
- Predicting Rates and Regioselectivity in Cytochrome P450 Mediated ReactionsR01GM084546 · NIGMS · WASHINGTON STATE UNIVERSITY · fiscal years 2008 to 2011 · $315,029 awarded in 2011Same name and institution; not confirmed by an ID
- Cytochrome P450 Models for Risk AssessmentR01ES009122 · NIEHS · WASHINGTON STATE UNIVERSITY · fiscal years 2000 to 2007 · $262,728 awarded in 2007Same name and institution; not confirmed by an ID
- Covalent Binding Methods for Early Drug DevelopmentR21CA101552 · NCI · WASHINGTON STATE UNIVERSITY · fiscal years 2003 · $146,800 awarded in 2003Same name and institution; not confirmed by an ID
- TRIPLE QUADRUPOLE MASS SPECTROMETERS10RR015844 · NCRR · WASHINGTON STATE UNIVERSITY · fiscal years 2001 · $330,034 awarded in 2001Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA016058 · NCI · OHIO STATE UNIVERSITY · PI David M Gosky · fiscal years 2013 to 2026Named on NCT01126502, NCT00112723
- U01CA076576RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01126502, NCT00112723
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 11:32 UTC. The ranking covers the 200 most relevant of 16 PubMed records, and a shared surname and initials can bring in a namesake. All 16 on PubMed
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.J Clin Oncol · 2015472 citationsRCR 12.9
- Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol · 2019309 citationsRCR 11.7
- 93 citationsRCR 4.2
- The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.Clin Cancer Res · 201679 citationsRCR 2.2
- 79 citationsRCR 3.9
- 76 citationsRCR 2.7
- Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.Blood Cancer J · 201671 citationsRCR 2.2
- 49 citationsRCR 1.7
- The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma.Clin Cancer Res · 202142 citationsRCR 1.8
- Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial.Clin Lymphoma Myeloma Leuk · 202141 citationsRCR 2.5